

**QCDR Measure:**

AAO-12: Age-Related Macular Degeneration: Disease Progression

**National Quality Strategy Domain:**

Effective Clinical Care

**Measure Type:**

Outcome (*Inverse measure*)

**Description:**

Percentage of patients with nonexudative age-related macular degeneration progressing to exudative age-related macular degeneration over the past 12 months.

**Instructions:**

This measure is to be reported a minimum of once per reporting period for patients seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with exudative age-related macular degeneration (in either one or both eyes) will submit this measure.

**Denominator:**

All patients aged 18 years of older with an active diagnosis of exudative age-related macular degeneration including documentation of the laterality (OD, OS, OU)

Denominator Criteria

Patients aged  $\geq 18$  years

AND

Diagnosis of Exudative Age-Related Macular Degeneration

- Exudative age-related macular degeneration (ICD-10: H35.32)

**Numerator:**

Patients who had an active diagnosis of nonexudative age-related macular degeneration in the past 12 months including documentation of the laterality (OD, OS, OU) and a history of taking AREDS supplements

Numerator Options:

Performance Met:

Patients who advanced from nonexudative AMD to exudative AMD in the past 12 months

Performance Not Met: Patients who did not advanced from nonexudative AMD to exudative AMD in the past 12 months

Patients are only eligible for the numerator when the disease advancement occurs in the same eye.

**Improvement Notation:**

Lower score indicates better performance